News in brief: JAK inhibitor indication extended; Elderly with GCA still benefit from IL-6 inhibitor; Low value from imaging low back pain

JAK1 inhibitor indication extended Upadacitinib (Rinvoq) has been registered in Australia for the treatment of moderate to severe active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS). The selective JAK1 inhibitor was currently only available in Australia – and PBS listed – for severe active rheumatoid arthritis. Upadacitinib, according to the Product Information, may be ...

Already a member?

Login to keep reading.

© 2021 the limbic